---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product comparison"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product comparison. Topics: Approved and investigational therapies for GA named by the sponsor, Competition from approved products stated by the sponsor, Sponsor contrast with C3 and C5 inhibitors: target and functional outcome, Sponsor characterization of comparator photoreceptor analyses, and 4 further topics. 8 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description/product-comparison"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Approved and investigational therapies for GA named by the sponsor

> “Two treatments are currently FDA-approved for GA, both receiving approval in 2023: Apellis’s Syfovre, a C3 inhibitor as well as Astellas’s avacincaptad pegol, a C5 inhibitor. There are currently no approved therapies for GA in the EU.”
> “Regeneron’s pozelimab, a C5 inhibiting monoclonal antibody combined with cemdisiran, a C5-targeted siRNA molecule dosed subcutaneously.”
> “In Phase 2, there are currently four complement-targeting agents: Aviceda Therapeutics’s AVD-104, a nanoparticle molecule that inhibits complement cascade amplification and inflammation pathways, Janssen’s JNJ-1887, a gene therapy candidate which expresses soluble CD59, a complement protein, Novartis’s iptacopan, an oral factor B inhibitor, and Perceive Bio’s VOY-101 molecule, the detailed mechanism of action of which has not been fully disclosed.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-2.1.2.14-2"></a>

### Competition from approved products stated by the sponsor

> “For example, with respect to vonaprument, there are two approved products for GA which may pose competition for vonaprument, if approved.”

Source: [Annexon Biosciences Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526453585/annx-20260930.htm)

<a id="topic-2.1.2.14-3"></a>

### Sponsor contrast with C3 and C5 inhibitors: target and functional outcome

> “C3/C5 designed to target the alternative pathway to preserve RPE cells/reduce lesion growth”
> “Protection of RPE has not resulted in preservation of vision”
> “Differentiated profile: small, non-pegylated, low viscosity, limited conversion to CNV”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

> “current FDA-approved treatments have not shown a meaningful functional benefit after years of treatment”

Source: [Annexon Biosciences ARCHER II registrational program press release (2023)](https://ir.annexonbio.com/news-releases/news-release-details/annexon-outlines-global-registrational-program-anx007-geographic)

<a id="topic-2.1.2.14-4"></a>

### Sponsor characterization of comparator photoreceptor analyses

> “Only studied non-foveal patients; No data available on central retinal domains”
> “Photoreceptor protection diminishes in central subfields, area critical for visual acuity”

Source: [Annexon Biosciences vonaprument presentation (2026)](https://ir.annexonbio.com/static-files/f03addd1-7cef-4b5b-b360-411d18ead57c)

<a id="topic-2.1.2.14-5"></a>

### Sponsor claim of vision preservation and the phase 2 primary endpoint result on which it rests

> “Vonaprument is the only investigational therapy in GA to show significant vision preservation on assessments of best corrected visual acuity, or BCVA, and low luminance visual acuity, or LLVA, demonstrating significant protection from vision loss in both normal and low light conditions, as well as significant preservation of central retinal photoreceptors necessary for visual acuity.”
> “Monthly treatment with vonaprument demonstrated nominally statistically significant reduction in BCVA ≥15-letter loss (p=0.0021) compared to sham.”
> “While the primary endpoint of mean rate of change (slope) in GA lesion area compared to sham at 12 months did not reach statistical significance, greater impact on retinal pigment epithelium loss was observed in the second six months of treatment versus the first.”

Source: [Annexon Biosciences Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131782/annx-20251231.htm)

<a id="topic-2.1.2.14-6"></a>

### Comparator dosing: pegcetacoplan

> “The recommended dose for SYFOVRE is 15 mg (0.1 mL of 150 mg/mL solution) administered by intravitreal injection to each affected eye once every 25 to 60 days.”

Source: [Apellis Pharmaceuticals Syfovre prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217171Orig1s003lbl.pdf)

<a id="topic-2.1.2.14-7"></a>

### Comparator dosing: avacincaptad pegol

> “The recommended dosage for IZERVAY is 2 mg (0.1 mL of 20 mg/mL solution) administered by intravitreal injection to each affected eye once monthly (approximately every 28 ± 7 days).”

Source: [Astellas Pharma US Izervay prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217225s004lbl.pdf)

<a id="topic-2.1.2.14-8"></a>

### Independent systematic review: no peer-reviewed clinical results for C1q inhibition

> “Although these therapies have progressed to clinical stages, no peer-reviewed publications reporting their clinical results are available to date. According to registry and sponsor-reported information, C1q blockade with ANX007 has progressed furthest among these candidates, advancing to Phase 3 trials following neuroprotective signals in Phase 2.”
> “As these results are not yet supported by peer-reviewed publications, they were not included in the evidence synthesis and are reported here for context only.”

Source: [Fernández-Muro et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13708414/)

<a id="topic-2.1.2.14-9"></a>

### Head-to-head trial data against pegcetacoplan or avacincaptad pegol

No evidence found.

Additional sources: [Rowe et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42999938/)

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
